Enpro Announces Date for First Quarter 2026 Earnings Release and Conference Call
Get Alerts NPO Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.4%
EPS Growth %: +14.3%
Join SI Premium – FREE
CHARLOTTE, N.C.--(BUSINESS WIRE)-- Enpro Inc. (NYSE: NPO) will release financial results for the first quarter of 2026 on Tuesday, May 5, at 6:30 a.m. Eastern Time. Eric Vaillancourt, President and Chief Executive Officer, and Joe Bruderek, Executive Vice President and Chief Financial Officer, will host a conference call to review the company’s performance at 8:30 a.m. Eastern Time.
The conference call will be webcast live at https://www.enpro.com, and may also be accessed via telephone at 1-877-407-0832, using the code 13750602. The webcast and telephone line will open approximately 10 minutes before the call. First quarter 2026 financial results and an accompanying slide presentation will be available on the company’s website.
About Enpro
Enpro is a leading industrial technology company focused on critical applications across many end-markets, including semiconductor, industrial process, commercial vehicle, sustainable power generation, aerospace, food and biopharma, photonics and life sciences. Headquartered in Charlotte, North Carolina, Enpro is listed on the New York Stock Exchange under the symbol “NPO”. For more information, visit the company’s website at https://www.enpro.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260421938777/en/
Investor Contacts:
James Gentile
Vice President, Investor Relations
Jenny Yee
Corporate Access Specialist
Phone: 704-731-1527
Email: [email protected]
Source: Enpro Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Torex Semiconductor Has Achieved "Zero" Current Consumption with Multi-Function Load Switch ICs XC8115/XC8116 Series
- Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
- Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share